This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cabot to Boost Global Carbon Black Capacity on Strong Demand
by Zacks Equity Research
Cabot's (CBT) latest move will expand its global carbon black capacity by more than 300,000 metric tons.
Cabot (CBT) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Solid performance in Reinforcement Materials and Performance Chemicals segments drives Cabot's (CBT) results in Q2.
Chemical Stock Earnings Slated on May 7: CBT, IFF & RYAM
by Zacks Equity Research
Chemical companies are expected to continue to gain from strategic measures this earnings season.
Cabot (CBT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot's (CBT) Q2 results are likely to benefit from continued momentum in the specialty applications and a favorable pricing environment amid higher fixed costs.
Cabot Inks Licensing Deal With Midwest Energy Emissions
by Zacks Equity Research
Cabot (CBT) inks deal with Midwest Energy Emissions, under which, it will leverage the latter's patented technologies to enhance its current portfolio of mercury removal solutions.
Cabot (CBT) Bolsters Specialty Compounds Business Globally
by Zacks Equity Research
Cabot (CBT) completes two expansion projects to increase manufacturing capacity to better serve global customers and grow in advanced polymeric materials.
Cabot to Supply New Activated Carbon for POETS Project
by Zacks Equity Research
Cabot's (CBT) Hydrodarco 4000 activated carbon being the most effective in removing PFOA has been selected by the NYSDEC to ensure safe drinking water for the residents of Town of Hoosick.
Zacks.com featured highlights include: United Natural, Western Digital, Conduent, ArcBest and Cabot
by Zacks Equity Research
Zacks.com featured highlights include: United Natural, Western Digital, Conduent, ArcBest and Cabot
Buy These 7 Low Price-to-Sales Stocks That Promise Growth
by Zacks Equity Research
A stock's price-to-sales ratio reflects how much investors are paying for each dollar of revenues generated by the company.
5 Stocks With Amazingly Low EV/EBITDA Ratios to Scoop Up
by Zacks Equity Research
We have screened value stocks based on EV/EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.
Monsanto (MON) Downgraded to Sell on Predominant Headwinds
by Zacks Equity Research
China's 25% tariffs (announced Apr 4) on agricultural products, like soybean, or headwinds, such as stiff industry rivalry, anticipated to dent Monsanto's (MON) profitability.
Monsanto Company (MON) Q2 Earnings Miss Estimates, Up Y/Y
by Zacks Equity Research
Monsanto's (MON) second-quarter fiscal 2018 earnings came in lower than the year-ago tally and missed the Zacks Consensus Estimate as well.
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Curtiss-Wright, Stepan, Mellanox Technologies and Cabot
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Curtiss-Wright, Stepan, Mellanox Technologies and Cabot
Should Value Investors Pick Cabot (CBT) Stock Now?
by Zacks Equity Research
Cabot (CBT) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
5 Top-Ranked U.S. Stocks to Gain From Trump's China Tariffs
by Nalak Das
The U.S. government imposed 25% tariffs targeting 1,300 Chinese imports for a total worth of $50 billion.
Companhia Siderurgica (SID) Posts Q4 Earnings, Sales Solid
by Zacks Equity Research
Companhia Siderurgica Nacional's (SID) fourth-quarter 2017 net earnings increase over the year-ago quarter's loss. Revenues increase 10.5% year over year on higher steel products and iron ore prices.
Here's Why You Should Add Univar (UNVR) to Your Portfolio
by Zacks Equity Research
Univar (UNVR) stands to gain from a strong demand for its services, solid overseas operations and meaningful acquisitions. Rewarding shareholders and making growth investments remain priorities.
Monsanto (MON) & Pairwise to Jointly Roll Out Agro Solutions
by Zacks Equity Research
Monsanto (MON) and agricultural start-up firm, Pairwise Plants, to jointly roll out breakthrough crop-yield enhancing solutions with gene-editing technology.
Here's Why You Should Add Cabot (CBT) Stock to Your Portfolio
by Anindya Barman
Healthy growth prospects and upbeat outlook make Cabot (CBT) an attractive investment option.
Eastman Chemical (EMN) to Raise Price of Choline Chloride
by Zacks Equity Research
Eastman Chemical (EMN) is taking appropriate actions amid an escalated raw material pricing environment.
Zacks.com highlights: ArcBest, Cabot, Avianca Holdings, PetroChina and Finish Line
by Zacks Equity Research
Zacks.com highlights: ArcBest, Cabot, Avianca Holdings, PetroChina and Finish Line
Tap 5 Value Stocks Sporting Enticing EV/EBITDA Ratios
by Zacks Equity Research
We have screened value stocks based on EV/EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.
Here's Why You Should Add Praxair (PX) to Your Portfolio
by Zacks Equity Research
Praxair (PX) stands to gain from a solid product portfolio and increasing applications of industrial gases. Returning value to shareholders is a priority.
Mosaic (MOS) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Solid performance across all segments contributed to Mosaic's (MOS) results in Q4.
Agnico Eagle (AEM) Tops on Q4 Earnings, Ups Production View
by Zacks Equity Research
While Agnico Eagle (AEM) has raised its production view for 2018, it sees a year-over-year increase in AISC this year.